Cameron J Parkin1, Daniel Gilbourd2, Richard Grills3,4, Sue Chapman5, Sydney Weinstein6, Neil Joshi7, Balasubramaniam Indrajit8, Jonathan Kam2, Teresa Smilovic4, Andrew Shepherd5, Njeri Gikenye7, Mark W Louie-Johnsun9,10,11. 1. Department of Urology, Gosford Hospital, Central Coast Local Health District, Holden St, Gosford, NSW, 2250, Australia. cameronjparkin@gmail.com. 2. Calvary Hospital, Bruce, ACT, Australia. 3. Department of Surgery, Deakin University, Geelong, VIC, Australia. 4. West Coast Urology, Geelong, VIC, Australia. 5. St. John of God Bunbury Hospital, College Grove, WA, Australia. 6. Hollywood Private Hospital, Nedlands, WA, Australia. 7. Coffs Harbour Health Campus, Coffs Harbour, NSW, Australia. 8. Dubbo Base Hospital, Dubbo, NSW, Australia. 9. Department of Urology, Gosford Hospital, Central Coast Local Health District, Holden St, Gosford, NSW, 2250, Australia. 10. School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia. 11. Gosford Private Hospital, North Gosford, NSW, Australia.
Abstract
PURPOSE: Worldwide, transrectal ultrasound-guided prostate needle remains the most common method of diagnosing prostate cancer. Due to high infective complications reported, some have suggested it is now time to abandon this technique in preference of a trans-perineal approach. The aim of this study was to report on the infection rates following transrectal ultrasound-guided prostate needle biopsy in multiple Australian centres. MATERIALS AND METHODS: Data were collected from seven Australian centres across four states and territories that undertake transrectal ultrasound-guided prostate needle biopsies for the diagnosis of prostate cancer, including major metropolitan and regional centres. In four centres, the data were collected prospectively. Rates of readmissions due to infection, urosepsis resulting in intensive care admission and mortality were recorded. RESULTS: 12,240 prostate biopsies were performed in seven Australian centres between July 1998 and December 2020. There were 105 readmissions for infective complications with rates between centres ranging from 0.19 to 2.60% and an overall rate of 0.86%. Admission to intensive care with sepsis ranged from 0 to 0.23% and overall 0.03%. There was no mortality in the 12,240 cases. CONCLUSION: Infective complications following transrectal ultrasound-guided prostate needle biopsies are very low, occurring in less than 1% of 12,240 biopsies. Though this study included a combination of both prospective and retrospective data and did not offer a comparison with a trans-perineal approach, TRUS prostate biopsy is a safe means of obtaining a prostate cancer diagnosis. Further prospective studies directly comparing the techniques are required prior to abandoning TRUS based upon infectious complications.
PURPOSE: Worldwide, transrectal ultrasound-guided prostate needle remains the most common method of diagnosing prostate cancer. Due to high infective complications reported, some have suggested it is now time to abandon this technique in preference of a trans-perineal approach. The aim of this study was to report on the infection rates following transrectal ultrasound-guided prostate needle biopsy in multiple Australian centres. MATERIALS AND METHODS: Data were collected from seven Australian centres across four states and territories that undertake transrectal ultrasound-guided prostate needle biopsies for the diagnosis of prostate cancer, including major metropolitan and regional centres. In four centres, the data were collected prospectively. Rates of readmissions due to infection, urosepsis resulting in intensive care admission and mortality were recorded. RESULTS: 12,240 prostate biopsies were performed in seven Australian centres between July 1998 and December 2020. There were 105 readmissions for infective complications with rates between centres ranging from 0.19 to 2.60% and an overall rate of 0.86%. Admission to intensive care with sepsis ranged from 0 to 0.23% and overall 0.03%. There was no mortality in the 12,240 cases. CONCLUSION: Infective complications following transrectal ultrasound-guided prostate needle biopsies are very low, occurring in less than 1% of 12,240 biopsies. Though this study included a combination of both prospective and retrospective data and did not offer a comparison with a trans-perineal approach, TRUS prostate biopsy is a safe means of obtaining a prostate cancer diagnosis. Further prospective studies directly comparing the techniques are required prior to abandoning TRUS based upon infectious complications.
Authors: Truls E Bjerklund Johansen; Per-Henrik Zahl; Eduard Baco; Riccardo Bartoletti; Gernot Bonkat; Franck Bruyere; Tommaso Cai; Mete Cek; Ekaterina Kulchavenya; Bela Köves; Vladimir Mouraviev; Adrian Pilatz; Zafer Tandogdu; Peter Tenke; Florian M E Wagenlehner Journal: World J Urol Date: 2019-06-10 Impact factor: 4.226
Authors: Robert K Nam; Refik Saskin; Yuna Lee; Ying Liu; Calvin Law; Laurence H Klotz; D Andrew Loblaw; John Trachtenberg; Aleksandra Stanimirovic; Andrew E Simor; Arun Seth; David R Urbach; Steven A Narod Journal: J Urol Date: 2013-01 Impact factor: 7.450
Authors: K Günzel; A Magheli; E Baco; H Cash; S Heinrich; H Neubert; J Schlegel; M Schostak; T Henkel; P Asbach; S Hinz Journal: World J Urol Date: 2021-04-18 Impact factor: 4.226
Authors: Tobias Kohl; August Sigle; Timur Kuru; Johannes Salem; Hanjo Rolfs; Tobias Kowalke; Rodrigo Suarez-Ibarrola; Jakob Michaelis; Nadine Binder; Cordula A Jilg; Arkadiusz Miernik; Markus T Grabbert; W Schultze-Seemann; Christian Gratzke; Daniel Porres Journal: Prostate Cancer Prostatic Dis Date: 2021-07-15 Impact factor: 5.455